Literature DB >> 25829198

Relationship between subclinical cardiac troponin I elevation and culprit lesion characteristics assessed by optical coherence tomography in patients undergoing elective percutaneous coronary intervention.

Tetsumin Lee1, Tadashi Murai1, Taishi Yonetsu1, Asami Suzuki1, Keiichi Hishikari1, Yoshihisa Kanaji1, Junji Matsuda1, Makoto Araki1, Takayuki Niida1, Mitsuaki Isobe1, Tsunekazu Kakuta2.   

Abstract

BACKGROUND: The prevalence of subclinical, cardiac troponin I (cTnI) elevation in stable patients undergoing elective percutaneous coronary intervention and its relationship to culprit lesion characteristics assessed by optical coherence tomography (OCT) are unknown. METHODS AND
RESULTS: We studied 206 native de novo culprit coronary lesions from 206 patients with stable angina pectoris who underwent OCT before elective percutaneous coronary intervention. Patients were divided into 2 groups according to the presence (cTnI group; n=47; 22.8%) or absence (non-cTnI group; n=159; 77.2%) of cTnI ≥0.03 ng/mL at admission. The clinical and OCT findings were compared between these 2 groups. No significant difference was found in the clinical presentation between the groups except for the serum C-reactive protein levels and presence of multivessel disease. By OCT, cTnI elevation was associated with the presence of thin-cap fibroatheromas, a greater lipid arc, and a longer lipid length. In a multivariable analysis, the presence of positive C-reactive protein levels (odds ratio, 4.38; 95% confidence interval, 1.90-10.08; P=0.001) and OCT-derived thin-cap fibroatheromas (odds ratio, 2.89; 95% confidence interval, 1.22-6.86; P=0.016) were independent predictors of cTnI elevation. Periprocedural myocardial injury, defined as postpercutaneous coronary intervention peak cTnI levels >1.0 ng/mL (5× the upper reference limit), occurred more often in patients with cTnI elevation at admission (cTnI group: 41% versus non-cTnI group: 18%; P=0.001).
CONCLUSIONS: The presence of subclinical cTnI elevation at admission was not uncommon and was associated with OCT-derived unstable plaque morphology in patients undergoing elective percutaneous coronary intervention, and may help to identify patients with stable angina pectoris at high risk for periprocedural myocardial injury.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  angioplasty; biomarker; coronary disease; imaging; plaque

Mesh:

Substances:

Year:  2015        PMID: 25829198     DOI: 10.1161/CIRCINTERVENTIONS.114.001727

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  4 in total

1.  Effects of trimetazidine on periprocedural microRNA-21 expression by CD4+ T lymphocytes in patients with unstable angina pectoris.

Authors:  Qiang Su; Lang Li; Jinmin Zhao; Yuhan Sun; Huafeng Yang
Journal:  Oncotarget       Date:  2017-09-18

Review 2.  Coronary plaque morphology on multi-modality imagining and periprocedural myocardial infarction after percutaneous coronary intervention.

Authors:  Akira Sato; Kazutaka Aonuma
Journal:  Int J Cardiol Heart Vasc       Date:  2016-03-17

Review 3.  The clinical approach to diagnosing peri-procedural myocardial infarction after percutaneous coronary interventions according to the fourth universal definition of myocardial infarction - from the study group on biomarkers of the European Society of Cardiology (ESC) Association for Acute CardioVascular Care (ACVC).

Authors:  Johannes Mair; Allan Jaffe; Bertil Lindahl; Nicholas Mills; Martin Möckel; Louise Cullen; Evangelos Giannitsis; Ola Hammarsten; Kurt Huber; Konstantin Krychtiuk; Christian Mueller; Kristian Thygesen
Journal:  Biomarkers       Date:  2022-05-26       Impact factor: 2.663

4.  Management and outcomes of patients with unstable angina with undetectable, normal, or intermediate hsTnT levels.

Authors:  Evangelos Giannitsis; Moritz Biener; Hauke Hund; Matthias Mueller-Hennessen; Mehrshad Vafaie; Jochen Gandowitz; Christoph Riedle; Julia Löhr; Hugo A Katus; Kiril M Stoyanov
Journal:  Clin Res Cardiol       Date:  2019-07-19       Impact factor: 5.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.